{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:22:18Z","timestamp":1787865738706,"version":"build-2784847793"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.atherosclerosis.2026.121850","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:13:54Z","timestamp":1784906034000},"page":"121850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lp(a) testing and treatment with Lp(a)-lowering therapies in the primary and secondary prevention of cardiovascular disease in high income countries: A preliminary health technology assessment"],"prefix":"10.1016","volume":"420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-5758","authenticated-orcid":false,"given":"Jedidiah I.","family":"Morton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-1120","authenticated-orcid":false,"given":"Florian","family":"Kronenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-6582","authenticated-orcid":false,"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4080-7963","authenticated-orcid":false,"given":"I\u00f1aki Guti\u00e9rrez","family":"Ibarluzea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia R.","family":"Kamstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.121850_b1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein (a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2026.121850_b2","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein (a) in alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: Mendelian randomization investigation","volume":"141","author":"Larsson","year":"2020","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2026.121850_b3","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein (a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"28","author":"Welsh","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2026.121850_b4","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein (a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"45","key":"10.1016\/j.atherosclerosis.2026.121850_b5","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1093\/eurheartj\/ehad583","article-title":"Economic burden of cardiovascular diseases in the European union: a population-based cost study","volume":"44","author":"Luengo-Fernandez","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b6","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001258","article-title":"Forecasting the economic burden of cardiovascular disease and stroke in the United States through 2050: A presidential advisory from the American heart association","author":"Kazi","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.121850_b7","first-page":"421","article-title":"Future burden of myocardial infarction in Australia: impact on health outcomes between 2019 and 2038","volume":"10","author":"Abebe","year":"2024","journal-title":"Eur Hear Journal-Quality Care Clin Outcomes"},{"issue":"10459","key":"10.1016\/j.atherosclerosis.2026.121850_b8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein (a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.08.012","article-title":"Early health technology assessment of gene silencing therapies for lowering lipoprotein (a) in the secondary prevention of coronary heart disease","author":"Burvill","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b10","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120447","article-title":"Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis","author":"Morton","year":"2025","journal-title":"Atherosclerosis"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2026.121850_b11","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.05.007","article-title":"Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment?","volume":"304","author":"Ademi","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b13","first-page":"S1098","article-title":"Lost therapeutic benefit of delayed LDL-C control in statin treated patients and cost-effectiveness analysis of lipid-lowering intensification","author":"Marquina","year":"2022","journal-title":"Value Health: J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.121850_b14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40273-023-01306-2","article-title":"Lipid-lowering strategies for primary prevention of coronary heart disease in the UK: a cost-effectiveness analysis","volume":"42","author":"Morton","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.121850_b15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamapediatrics.2023.0763","article-title":"Cost-effectiveness and return on investment of a nationwide case-finding program for familial hypercholesterolemia in children in the Netherlands","volume":"177","author":"Ademi","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2026.121850_b16","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jval.2024.07.010","article-title":"A causal model for primary prevention of cardiovascular disease: the health economic model for the primary prevention of cardiovascular disease","volume":"27","author":"Morton","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b17","first-page":"1","article-title":"Immediate versus 5-year risk-guided initiation of treatment for primary prevention of cardiovascular disease for Australians aged 40 years: A health economic analysis","author":"Morton","year":"2024","journal-title":"PharmacoEconomics"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2026.121850_b18","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/jama.2019.14120","article-title":"Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease","volume":"322","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11869-010-0082-7","article-title":"How is cardiovascular disease mortality risk affected by duration and intensity of fine particulate matter exposure? An integration of the epidemiologic evidence","volume":"4","author":"Pope","year":"2011","journal-title":"Air Qual Atmosphere & Health"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2026.121850_b20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein (a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","article-title":"AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users","volume":"34","author":"Vemer","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.121850_b22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLOS Med"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2026.121850_b23","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1002\/sim.2764","article-title":"Age\u2013period\u2013cohort models for the Lexis diagram","volume":"26","author":"Carstensen","year":"2007","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.121850_b24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001989","article-title":"Time trends in the incidence of clinically diagnosed type 2 diabetes and pre-diabetes in the UK 2009\u20132018: a retrospective cohort study","volume":"9","author":"Pal","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"34","key":"10.1016\/j.atherosclerosis.2026.121850_b25","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2026.121850_b26","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"ESC Cardiovasc Risk Collaboration and SCORE2 Working Group","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.121850_b27","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10557-021-07199-7","article-title":"Switching, persistence and adherence to statin therapy: a retrospective cohort study using the Australian national pharmacy data","volume":"36","author":"Talic","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.121850_b28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jsps.2023.04.002","article-title":"Statins utilization trends and expenditures in the US before and after the implementation of the 2013 ACC\/AHA guidelines","volume":"31","author":"Matyori","year":"2023","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.amjcard.2022.10.013","article-title":"Ten-year evolution of statin eligibility and use in a population-based cohort","volume":"187","author":"Rochat","year":"2023","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.121850_b30","article-title":"Atorvastatin for lowering lipids","author":"Adams","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2026.121850_b31","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.atherosclerosis.2026.121850_b32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein (a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.121850_b33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein (a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b34","series-title":"The pharmaceutical benefits advisory committee (PBAC) guidelines","author":"Department of Health","year":"2021"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b35","series-title":"Guide to the methods of technology appraisal","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b36","series-title":"Health expenditure Australia 2022-23","author":"Australian Institute of Health and Welfare","year":"2024"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b37","series-title":"Personal social services research unit, university of kent. Unit costs of health and social care 2023. 12 sources of information. 12.1 inflation indices. 12.1.1 the NHS cost inflation index (NHSCII)","year":"2024"},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2026.121850_b38","article-title":"The value of productivity: human-capital versus friction-cost method","volume":"69","author":"Van den Hout","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40273-017-0585-2","article-title":"Estimating the reference incremental cost-effectiveness ratio for the Australian health system","volume":"36","author":"Edney","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b40","doi-asserted-by":"crossref","first-page":"w14626","DOI":"10.4414\/smw.2018.14626","article-title":"Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight","volume":"148","author":"Ademi","year":"2018","journal-title":"Swiss Med Wkly"},{"issue":"34","key":"10.1016\/j.atherosclerosis.2026.121850_b41","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1093\/eurheartj\/ehab770","article-title":"Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis","volume":"43","author":"Marquina","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b42","series-title":"Health spending","author":"Organisation for Economic Co-operation and Development","year":"2024"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b43","series-title":"Purchasing power parities (PPP)","author":"Organisation for Economic Co-operation and Development","year":"2024"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b44","series-title":"Average annual wages","author":"Organisation for Economic Co-operation and Development","year":"2024"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.121850_b45","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","article-title":"Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures","volume":"11","author":"Pichon-Riviere","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"42","key":"10.1016\/j.atherosclerosis.2026.121850_b46","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b47","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","author":"Blumenthal","year":"2026","journal-title":"JACC"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2026.121850_b48","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated ldl cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b49","series-title":"The Pharmaceutical Benefits Scheme. General Schedule. Inclisiran, post=Available at: . [Accessed 19 March 2025]","year":"2025"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b50","series-title":"National health service dictionary of medicines and devices. Actual medicinal product pack (AMPP). Leqvio 284mg\/1.5ml solution for injection pre-filled syringes (novartis pharmaceuticals UK ltd) 1 pre-filled disposable injection","year":"2024"},{"issue":"39","key":"10.1016\/j.atherosclerosis.2026.121850_b51","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.121850_b52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein (a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b53","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155347","article-title":"Circulating lipoprotein (a) levels and health outcomes: Phenome-wide mendelian randomization and disease-trajectory analyses","volume":"137","author":"Larsson","year":"2022","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2026.121850_b54","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/aje\/kwx246","article-title":"Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population","volume":"186","author":"Fry","year":"2017","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.atherosclerosis.2026.121850_b55","article-title":"Cardiovascular disease care and outcomes in west and south European countries","volume":"33","author":"Timmis","year":"2023","journal-title":"Lancet Reg Health\u2013Europe"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.121850_b56","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein (a) a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"Jama"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2026.121850_b57","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2022.09.021","article-title":"Equivalent impact of elevated lipoprotein (a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease","volume":"80","author":"Hedegaard","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026012165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026012165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:56:22Z","timestamp":1787864182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026012165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":57,"alternative-id":["S0021915026012165"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.121850","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lp(a) testing and treatment with Lp(a)-lowering therapies in the primary and secondary prevention of cardiovascular disease in high income countries: A preliminary health technology assessment","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.121850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121850"}}